Aims. To describe the epidemiology of acetabular fractures including patient characteristics, injury mechanisms,
Aims. The aims of this study were to evaluate the incidence of reoperation (all cause and specifically for periprosthetic femoral fracture (PFF)) and mortality, and associated risk factors, following a hemiarthroplasty incorporating a cemented collarless polished taper slip stem (PTS) for management of an intracapsular hip
Aims. To identify factors influencing clinicians’ decisions to undertake a nonoperative hip
Aims. United Classification System (UCS) B2 and B3 periprosthetic
Aims. Cementing in arthroplasty for hip
Aims. Total hip arthroplasty (THA) is considered the preferred treatment for displaced proximal femoral neck
Aims. The primary aim of this study was to compare surgical methods (sliding hip screw (SHS) vs intramedullary nailing (IMN)) for trochanteric hip
Aims. The aim of this study was to explore the functional results in a fitter subgroup of participants in the Hip
Aims. Our primary aim was to assess reoperation-free survival at one year after the index injury in patients aged ≥ 75 years treated with internal fixation (IF) or arthroplasty for undisplaced femoral neck
Aims. To develop prediction models using machine-learning (ML) algorithms for 90-day and one-year mortality prediction in femoral neck
Aims. In UK there are around 76,000 hip
Aims. The localization of necrotic areas has been reported to impact the prognosis and treatment strategy for osteonecrosis of the femoral head (ONFH). Anteroposterior localization of the necrotic area after a femoral neck
Aims. The Exeter V40 cemented polished tapered stem system has demonstrated excellent long-term outcomes. This paper presents a systematic review of the existing literature and reports on a large case series comparing implant
Aims. Delirium is associated with adverse outcomes following hip
Aims. This study evaluates risk factors influencing
Aims. Hip
Aims. This study aimed to describe preoperative waiting times for surgery in hip
Aims. The aim of the HIPGEN consortium is to develop the first cell therapy product for hip
Aims. The coronavirus disease (COVID)-19 pandemic forced an unprecedented period of challenge to the NHS in the UK where hip
Aims. Hip